Otsuka Holdings Co., Ltd. OTSKY
Set alert
As of Nov 2, 2:44 PM ET
- YTD
- +31.59%
- 1 year
- +37.21%
- Open
- 37.17
- Prev close
- 37.71
- Mkt cap
- 39.06B
- Vol
- 1.69K
- Avg vol
- 44.80K
- EPS
- 2.33
- P/E
- 16.00
More statistics
- Low
- 37.17
- High
- 37.31
- Earnings
- Oct 30, 2026
News
3 weeks ago defenseworld.net
Otsuka (OTCMKTS:OTSKY) Shares Gap Down – Here’s Why
Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTCMKTS:OTSKY - Get Free Report) shares gapped down before the market opened on Monday. The stock had previously closed at $36.92, but opened at $34.99.…
1 month ago defenseworld.net
Critical Survey: Inhibikase Therapeutics (NASDAQ:IKT) and Otsuka (OTCMKTS:OTSKY)
Otsuka (OTCMKTS:OTSKY - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two…
1 month ago reuters.com
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Otsuka Pharmaceutical and Ionis Pharmaceuticals said on Tuesday their experimental drug met the main goal of a late-stage study in patients with a rare inherited form of amyotrophic lateral…
1 month ago businesswire.com
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Ionis Pharmaceuticals, Inc. today announced…
2 months ago seekingalpha.com
Otsuka Holdings Co., Ltd. (OTSKY) Discusses 24-Month eGFR Results of Sibeprenlimab in IgA Nephropathy from Phase III VISIONARY Study Prepared Remarks Transcript
Otsuka Holdings Co., Ltd. (OTSKY) Discusses 24-Month eGFR Results of Sibeprenlimab in IgA Nephropathy from Phase III VISIONARY Study Prepared Remarks Transcript
2 months ago seekingalpha.com
Otsuka Holdings Co., Ltd. (OTSKY) Q2 2026 Earnings Call Prepared Remarks Transcript
Otsuka Holdings Co., Ltd. (OTSKY) Q2 2026 Earnings Call Prepared Remarks Transcript
3 months ago seekingalpha.com
Aristotle Global Equity Advisory Q2 2026 Portfolio Review
For the second quarter of 2026, Aristotle Capital's Global Equity WM Composite posted a total return of 6.92% pure gross of fees (6.40% net of fees), underperforming the MSCI ACWI Index, which…
3 months ago prnewswire.com
Otsuka ICU Medical LLC Announces Over $500M Expansion of IV Solutions Manufacturing in North America
This expansion of IV solutions manufacturing will help enhance supply-chain resiliency, support portfolio development and advance non-DEHP innovation for the North American IV solutions market. Joint…
6 months ago defenseworld.net
AstraZeneca (OTCMKTS:AZNCF) versus Otsuka (OTCMKTS:OTSKY) Financial Review
AstraZeneca (OTCMKTS:AZNCF - Get Free Report) and Otsuka (OTCMKTS:OTSKY - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the…
6 months ago seekingalpha.com
Otsuka Holdings Co., Ltd. (OTSKY) M&A Call Prepared Remarks Transcript
Otsuka Holdings Co., Ltd. (OTSKY) M&A Call Prepared Remarks Transcript
7 months ago defenseworld.net
Santen Pharmaceutical (OTCMKTS:SNPHY) & Otsuka (OTCMKTS:OTSKY) Financial Review
Otsuka (OTCMKTS:OTSKY - Get Free Report) and Santen Pharmaceutical (OTCMKTS:SNPHY - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies…
7 months ago defenseworld.net
Contrasting Otsuka (OTCMKTS:OTSKY) and Mayne Pharma Group (OTCMKTS:MAYNF)
Mayne Pharma Group (OTCMKTS:MAYNF - Get Free Report) and Otsuka (OTCMKTS:OTSKY - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses…
8 months ago seekingalpha.com
Otsuka Holdings Co., Ltd. (OTSKY) Q4 2025 Earnings Call Prepared Remarks Transcript
Otsuka Holdings Co., Ltd. (OTSKY) Q4 2025 Earnings Call Prepared Remarks Transcript
8 months ago accessnewswire.com
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) Meg Flippin, Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / February 19,…
8 months ago benzinga.com
Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment
William Blair upgrades Neumora after strong Alzheimer's agitation data, sees upside from NMRA-511 and obesity pipeline potential.
9 months ago globenewswire.com
Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
February 4, 2026 Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models…
9 months ago benzinga.com
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle
CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding to include Part B drugs.
9 months ago zacks.com
Recent Price Trend in Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) could be a great choice.
10 months ago zacks.com
Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) could be a great choice.
10 months ago zacks.com
Here's Why Momentum in Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) Should Keep going
Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move.
11 months ago reuters.com
US FDA approves Otsuka's kidney disease drug
The U.S. Food and Drug Administration has approved Otsuka's injectable drug to treat patients with a potentially life-threatening kidney disease, the health regulator's website showed on Tuesday.
11 months ago globenewswire.com
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to receive $85 million in upfront cash and expects to…
-
6 years ago benzinga.com
Earnings Scheduled For August 7, 2020
Companies Reporting Before The Bell • Canadian Solar Inc. (NASDAQ:CSIQ) is expected to report quarterly loss at $0.04 per share on revenue of $662.95 million.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Friday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Monday
Stocks That Hit 52-Week Highs On Monday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Friday